FL与辐射造血损伤

于丽梅; 陈肖华

FL与辐射造血损伤

于丽梅 , 陈肖华

文章导航 > 国际放射医学核医学杂志 > 2003, 27 > 5: (232-235)

引用本文:

Citation:

FL与辐射造血损伤

于丽梅¹,
陈肖华²

1. 132000 吉林, 北华大学;
2. 100850 北京, 军事医学科学院放射医学研究所放射病实验治疗研究室

作者简介: 于丽梅(1978-),女,硕士研究生,主要从事实验血液学研究;陈肖华(1958-),男,副研究员,主要从事放射病实验治疗研究。;

中图分类号: Q506;R811.03

FL and radiation hematopoietic injury

YU Li-mei¹,
CHEN Xiao-hua²

1. Medical College of Beihua University, Jilin 132000;
2. Institute of Radiation Medicine, Academy of Military Medical Science, Beijing 100850, China
CLC number: Q506;R811.03

摘要: FL(flt3 ligand)是一种作用于早期造血细胞的生长因子,通过与其受体flt3特异性结合,促进造血干、祖细胞增殖分化。最近的研究表明,在骨髓造血功能障碍时,FL蛋白水平发生明显变化。机体辐射损伤后,血浆中FL水平升高;FL水平有可能作为辐射导致骨髓损伤的生物学指标。另外,FL单独、或与其他细胞因子联合应用具有辐射损伤防治作用。
- FL /
- 造血 /
- 辐射
Abstract: FL (flt3 ligand)is an early acting hematopoietic cytokine.By binding and activating its specific tyro-sine kinase receptor flt3,FL can stimulate the proliferation and differentiation of hematopoietic stem and progeni-tor cells.Recently,it has been shown that the level of FL in plasma of patients with bone marrow aplasia in-creases dramatically.Plasma level of FL also can be elevated and is a possible bio-indicator for bone marrow aplasia in radiation-induced damage.Furthermore,FL,alone or in combination with other cytokines,provides protection from bone marrow aplasia after radiation.
- flt3 ligand /
- hematopoiesis /
- radiation
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Shurin MR, Esche C, Lotze MT, et al. FLT3: receptor and ligand. Biology and potential clinical application[J]. Cytokine Growth Factor Rev, 1998, 9(1): 37-48.
[2]	Lyman SD, Jacobsen SE. C-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities[J]. Blood, 1998, 91(4): 1101-1134.
[3]	McClanahan T, Culpepper J, Campbell D, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand[J]. Blood, 1996, 88(9): 3371-3382.
[4]	Chklovskaia E, Jansen W, Nissen C, et al. Mechaniam of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hemotopoiesis[J]. Blood, 1999, 93(8): 2595-2604.
[5]	Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15[J]. Blood, 1998, 92(10): 3647-3657.
[6]	Wonder-Filipowicz A, Lyman SD, Gratwohl A, et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia[J]. Blood, 1996, 88(12): 4493-4499.
[7]	Pfister 0, Chklovskaia E, Jansen W, et al. Chronic overexpression of membrane-bound flt3 ligand by T lymphocytes in severe aplastic anemia[J]. Br J Haematol, 2000, 109(1): 211-220.
[8]	Haidar JH, Bazarbachi A, Mahfouz R, et al. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization[J]. Hematother Stem Cell Res, 2002, 11(3): 533-538.
[9]	Gazitt Y, Liu Q. High steady-state plasma levels of flt3-lig-and in the peripheral blood is a good predictor for poor mobilization of CD34+PBSC in patients undergoing high-dose chemotherapy and stem cell rescue[J]. J Hematother Stem Cell Res, 2000, 9(2): 285-293.
[10]	Zwierzina H, Anderson JE, Rollinger-Holzinger I, et al. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes[J]. Leukemia, 1999, 13(4): 553-557.
[11]	Chklovskaia E, Nissen C, Landmann L, et al. Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor (-chain signaling and inhibited by cyclospoyin A[J]. Blood, 2001, 97(4): 1027-1034.
[12]	Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligandin plasma: a possible new bio-indicator for radiation-induced aplasia[J]. Int J Radiat Biol, 2001, 77(6): 703-712.
[13]	Blumenthal RD, Walter L, Malik J, et al. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy[J]. Cancer, 2000, 88(2): 333-343.
[14]	Hudak S, Leach MW, Xu Y, et al. Radioprotective effects of flk2/flt3 ligand[J]. Exp Hematol,1998, 26(6): 515-522.
[15]	Gratwohl A, John L, Baldomero H, et al. FLT-3 ligand pro-vides hematopoietic protection from total body irradiation in rabbits[J]. Blood, 1998, 92(3): 765-769.
[16]	Du N, Feng K, Luo CJ, et al. Radioprotective effect of FLT3 ligand expression regulated by Egr-1 regulated element on radiation injury of SCID mice[J]. Exp Hematol, 2003, 31(3): 191-196.

[1]	王治东 . GM-CSF在辐射后的变化及其在辐射损伤治疗中的应用. 国际放射医学核医学杂志, 2003, 27(1): 38-41.
[2]	周华云 , 王国权 , 周剑影 , 罗成基 . 白细胞介素-6用于辐射损伤的治疗. 国际放射医学核医学杂志, 1996, 20(6): 265-267.
[3]	高颖 . 辐射对骨髓造血微环境影响的研究进展. 国际放射医学核医学杂志, 2000, 24(4): 183-185.
[4]	陆颖 . 辐射诱发的旁效应研究. 国际放射医学核医学杂志, 2001, 25(5): 225-228.
[5]	庄永志 , 王俊杰 . 辐射诱发的二重癌. 国际放射医学核医学杂志, 2002, 26(3): 137-140.
[6]	姚莉 . 辐射损伤与细胞周期. 国际放射医学核医学杂志, 2004, 28(1): 33-36.
[7]	高洋 . 存活素与辐射诱导的凋亡. 国际放射医学核医学杂志, 2003, 27(5): 236-238.
[8]	王小华 , 余争平 , 程天民 . 角质细胞生长因子及其辐射防护作用. 国际放射医学核医学杂志, 1999, 23(5): 233-235.
[9]	古桂雄 . 辐射诱导发育脑细胞凋亡的分子调节. 国际放射医学核医学杂志, 2000, 24(2): 82-85.
[10]	杜利清 , 刘强 , 樊飞跃 . 核辐射事故后的公众健康保护. 国际放射医学核医学杂志, 2012, 36(3): 191-191. doi: 10.3760/cma.j.issn.1673-4114.2012.03.019

点击查看大图

计量

文章访问数: 1082
HTML全文浏览量: 100
PDF下载量: 2

FL与辐射造血损伤

于丽梅¹
陈肖华²

作者简介:于丽梅(1978-),女,硕士研究生,主要从事实验血液学研究;陈肖华(1958-),男,副研究员,主要从事放射病实验治疗研究。

1. 132000 吉林, 北华大学;
2. 100850 北京, 军事医学科学院放射医学研究所放射病实验治疗研究室

收稿日期: 2003-05-20

关键词:

FL /
造血 /
辐射

摘要: FL(flt3 ligand)是一种作用于早期造血细胞的生长因子,通过与其受体flt3特异性结合,促进造血干、祖细胞增殖分化。最近的研究表明,在骨髓造血功能障碍时,FL蛋白水平发生明显变化。机体辐射损伤后,血浆中FL水平升高;FL水平有可能作为辐射导致骨髓损伤的生物学指标。另外,FL单独、或与其他细胞因子联合应用具有辐射损伤防治作用。